Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

ABSTRACT: This nationwide, multicenter, open-label, single-arm study evaluated the efficacy and safety of the oral proteasome inhibitor (PI), ixazomib plus lenalidomide (LEN) and dexamethasone (DEX) (IRd) following injectable PI-based therapy for relapsed/refractory multiple myeloma (RRMM). Of 45 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Yu, Sasaki, Makoto, Takezako, Naoki, Ito, Shigeki, Suzuki, Kazuhito, Handa, Hiroshi, Chou, Takaaki, Yoshida, Takahiro, Mori, Ikuo, Shinozaki, Tomohiro, Suzuki, Kenshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444638/
https://www.ncbi.nlm.nih.gov/pubmed/37341778
http://dx.doi.org/10.1007/s00277-023-05212-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444638/
https://www.ncbi.nlm.nih.gov/pubmed/37341778
http://dx.doi.org/10.1007/s00277-023-05212-7

Ejemplares similares